

# Publikationsverzeichnis Prof. Dr. med. Oliver Bähr

---

## Originalarbeiten (Peer Review)

- |  | IF<br>(Jahr der Publikation) |
|--|------------------------------|
| 61. <i>Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.</i><br>Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. <i>JAMA Oncol.</i> 2020 May 21:e201024.  | 22.4<br>(2018)               |
| 60. <i>Quantitative T1 Mapping Indicates Tumor Infiltration Beyond the Enhancing Part of Glioblastomas.</i><br>Nöth U, Tichy J, Tritt S, Bähr O, Deichmann R, Hattingen E. <i>NMR Biomed.</i> 2020 Mar;33(3):e4242.  | 3.4.<br>(2018)               |
| 59. <i>Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.</i><br>Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW. <i>J Clin Med.</i> 2019 Nov 21;8(12):2031.   | 2.0<br>(2018)                |
| 58. <i>Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma With Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.</i><br>Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y. <i>Cancer Immunol Res.</i> 2019 Dec;7(12):1910-1927.  | 8.6<br>(2018)                |
| 57. <i>Health-related Quality of Life and Neurocognitive Functioning With Lomustine-Temozolomide Versus Temozolomide in Patients With Newly Diagnosed, MGMT-methylated Glioblastoma (CeTeG/NOA-09): A Randomised, Multicentre, Open-Label, Phase 3 Trial</i><br>Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, <b>Bähr O</b> , Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. <i>Lancet Oncol.</i> 2019 Oct;20(10):1444-1453. | 36.4<br>(2017)               |
| 56. <i>Baseline T1 Hyperintense and Diffusion-Restricted Lesions Are Not Linked to Prolonged Survival in Bevacizumab-Treated Glioblastoma Patients of the GLARIUS Trial.</i><br>Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. <i>J Neurooncol.</i> 2019 Sep;144(3):501-509.                                  | 3.1<br>(2018)                |

55. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, **Bähr O**, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet*. 2019 Feb 16;393(10172):678-688. 53.3 (2017)
54. Wenger KJ, Hattingen E, Harter PN, Richter C, Franz K, Steinbach JP, **Bähr O**, Pilatus U. Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS. *NMR Biomed*. 2019 Jan;32(1):e4027. 3.0 (2017)
53. Burger MC, Wagner M, Franz K, Harter PN, **Bähr O**, Steinbach JP, Senft C. Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. *J Clin Med*. 2018 Aug 14;7(8). 5.7 (2017)
52. Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, **Bähr O**, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. *J Cancer Res Clin Oncol*. 2018 Aug;144(8):1581-1589. 3.3 (2017)
51. Quick-Weller J, Tichy J, Harter PN, Tritt S, Baumgarten P, **Bähr O**, Dinc N, Behmanesh B, Weise L, Seifert V, Marquardt G. "Two is not enough" - Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma. *J Clin Neurosci*. 2018 Jan;47:311-314. 1.6 (2016)
50. Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, **Bähr O**, Steinbach JP. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. *Oncol Rep*. 2017 Dec;38(6):3291-3296. 2.7 (2016)
49. Wenger K, Hattingen E, Franz K, Steinbach J, **Bähr O**\*, Pilatus U\*. In vivo metabolic profiles determined by 31P MR spectroscopy do not differ between patients with IDH wildtype and IDH mutant gliomas. *Clin Neuroradiol*. 2017 Oct 5. [Epub ahead of print] 2.6 (2016)  
\* these authors contributed equally to this work

48. Burger MC, Ronellenfitsch MW, Lorenz N, Wagner M, Voss M, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Senft C, Harter PN, **Bähr O**. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. *Oncol Rep*. 2017 Dec;38(6):3291-3296. 2.7 (2016)
47. Burger MC, Harter PN, Franz K, Steinbach JP, Wagner M, **Bähr O**. Pitfalls in the diagnosis and care of patients with suspected neurosarcoidosis: A retrospective analysis *Curr Trends Neurol*. 2017, 11:23-30. -
46. **Bähr O**, Gross S, Harter PN, Kirches E, Mawrin C, Steinbach JP, Mittelbronn M. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. *Oncol Lett*. 2017 Nov;14(5):5443-5451. 1.4 (2016)
45. Hassel JC, Heinzerling L, Aberle J, **Bähr O**, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. *Cancer Treat Rev*. 2017 May 18;57:36-49. 8.6 (2016)
44. Burger MC, Mildenerger IC, Wagner M, Mittelbronn M, Steinbach JP, **Bähr O**. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. *Int J Mol Sci*. 2017 Mar 29;18(4). 3.2 (2016)
43. Wenger K, Wagner M, You S, Franz K, Harter PN, Burger M, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, **Bähr O**. Bevacizumab as last line treatment for glioblastoma after failure of radiotherapy, temozolomide and lomustine. *Oncology letters*. 2017. Accepted 1.4 (2016)
42. Wenger K, Hattingen E, Franz K, Steinbach JP, **Bähr O\***, Pilatus U\*. Intracellular pH measured by <sup>31</sup>P-MR-Spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy. *J Magn Reson Imaging*. 2017 Feb 6. [Epub ahead of print] 3.1 (2016)  
\* these authors contributed equally to this work
41. Steidl E, Pilatus U, Hattingen E, Steinbach JP, Zanella F, Ronellenfitsch MW, **Bähr O**. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A <sup>1</sup>H-Magnetic Resonance Spectroscopy Study. *PLoS One*. 2016 Dec 29;11(12):e0168113. 2.8

40. Kortland LM, Alfter A, **Bähr O**, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, Reese JP, Runge U, Senft C, Steinmetz H, Rosenow F, Strzelczyk A. 5.3  
*Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany.*  
*Epilepsia.* 2016 Dec;57(12):2056-2066.
39. Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiebold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M\*, **Bähr O**\*. 3.0  
*Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.*  
*J Neurooncol.* 2016 Aug;129(1):93-100.  
 \* these authors contributed equally to this work
38. Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, **Bähr O**, Trojan J. 0.3  
*Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis.* (2015)  
*J Gastrointest Cancer.* 2016 Mar;47(1):82-8.
37. Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, **Bähr O**, Mäder L, Goepfert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M. 7.8  
*Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.*  
*Neuro Oncol.* 2016 Feb;18(2):173-83.
36. Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, **Bähr O**, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G. 12.2  
*Gliomatosis cerebri: no evidence for a separate brain tumor entity.*  
*Acta Neuropathol.* 2016 Feb;131(2):309-19.
35. Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, **Bähr O**, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y. 9.5  
*Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.*  
*EMBO Mol Med.* 2015 Dec 14;8(1):39-57.
34. Meyer-Ohlendorf M, Braczynski A, Al-Qaisi O, Gessler F, Biskup S, Weise L, Steinbach JP, Wagner M, Mittelbronn M, **Bähr O**. 2.0  
*Comprehensive diagnostics in a case of hereditary diffuse leukodystrophy with spheroids.*  
*BMC Neurol.* 2015 Jul 4;15:103.

33. Thiebold AL, Luger S, Wagner M, Filmann N, Ronellenfitsch MW, Harter PN, Braczynski AK, Dützmann S, Hattingen E, Steinbach JP, Senft C, Rieger J, **Bähr O**. Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. *Oncotarget*. 2015 Jun 10;6(16):14537-44. 5.0
32. Nöth U, Hattingen E, **Bähr O**, Tichy J, Deichmann R. Improved visibility of brain tumors in synthetic MP-RAGE anatomies with pure T1 weighting. *NMR Biomed*. 2015 Jul;28(7):818-30. 3.0
31. Blasel S, Zagorcic A, Jurcoane A, **Bähr O**, Wagner M, Harter PN, Hattingen E. Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence. *J Neuroimaging*. 2016 Jan-Feb;26(1):116-23. 2.8
30. Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, **Bähr O**, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. *Clin Cancer Res*. 2015 May 1;21(9):2057-64. 8.7
29. Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, **Bähr O**, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. *Acta Neuropathol*. 2015 Jan;129(1):115-31. 11.4
28. Lescher S, Jurcoane A, Veit A, **Bähr O**, Deichmann R, Hattingen E. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. *Neuroradiology*. 2015 Jan;57(1):11-20. 2.3
27. **Bähr O**, Harter PN, Weise LM, You S, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. *Neurology* 2014 Jul 15;83(3):227-34. 8.3
26. Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, **Bähr O**, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M. Confounding Factors in Diagnostics of MGMT Promoter Methylation Status in Glioblastomas in Stereotactic Biopsies. *Stereotact Funct Neurosurg*. 2014 Apr 24;92(3):129-139. 2.1

25. Fischer S\*, Ronellenfitsch MW\*, Thiebold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, **Bähr O**. Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. *PLoS One*. 2014 Apr 17;9(4):e94921. \* these authors contributed equally to this work 3.2
24. Rieger J\*, **Bähr O**\*, Maurer G\*, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol*. 2014 Jun;44(6):1843-52. \* these authors contributed equally to this work 3.0
23. Hattingen E, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, **Bähr O**. Quantitative T2-mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival *Neuro Oncol*. 2013 Oct;15(10):1395-404. 5.3
22. Blasel S, Jurcoane A, **Bähr O**, Weise L, Harter PN, Hattingen E. MR perfusion in and around the contrast-enhancement of primary CNS lymphomas. *J Neurooncol*. 2013 Aug;114(1):127-34. 2.8
21. Hattingen E, **Bähr O**, Rieger J, Blasel S, Steinbach J, Pilatus U. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. *PLoS One* 2013;8(3):e56439. 3.5
20. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol*. 2012 Jul;13(7):707-15. **(listed as a collaborator)** 25.1
19. Wanka C, Brucker DP, **Bähr O**, Ronellenfitsch M, Weller M, Steinbach JP, Rieger J. Synthesis of Cytochrome c Oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. *Oncogene* 2012 Aug 16;31(33):3764-76 7.4

18. **Bähr O**, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP. 1.5  
*Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO trial. Acta neurochir (Wien) 2012;154:229-35.*
17. Hattingen E, Jurcoane A, **Bähr O**, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. 5.7  
*Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 2011;13:1349-63.*
16. Maurer GD, Brucker DP, **Bähr O**, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J. 3.0  
*Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 2011, Jul 26;11:315.*
15. **Bähr O**, Hattingen E, Rieger J, Steinbach JP. 5.7  
*Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in glioblastoma patients. Neuro Oncol. 2011;13:1020-9.*
14. Glas M\*, **Bähr O**\*, Felsberg J\*, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U, for the Neuro-Oncology Group of the German Cancer Society. 11.1  
*NOA-05 phase II trial of procarbazine and CCNU therapy in gliomatosis cerebri Ann Neurol 2011;70:445-53.  
 \* these authors contributed equally to this work*
13. Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, **Bähr O**, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Ninkovic G, Löffler M, Weller M, Westphal M; German Glioma Network. 8.0  
*Complementary therapy use in patients with glioma: an observational study. Neurology. 2010;75:2229-35.*
12. Rieger J, **Bähr O**, Ronellenfitsch MW, Steinbach J, Hattingen E. 19.0  
*Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia? J Clin Oncol. 2010;28:e477.*
11. Rieger J, **Bähr O**, Müller K, Franz K, Steinbach J, Hattingen E. 2.9  
*Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. 2010;99:49-56.*

10. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, **Bähr O**, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Chemoradiotherapy of Newly Diagnosed Glioblastoma with Intensified Temozolomide. *Int J Radiat Oncol Biol Phys.* 2010;77:670-6. 4.5
9. **Bähr O**, Herrlinger U, Weller M, Steinbach JP. Very late relapses in glioblastoma long-term survivors. *J Neurol.* 2009;256:1756-8. 2.9
8. Glas M, Happold C, Rieger J, Wiewrodt D, **Bähr O**, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. *J Clin Oncol.* 2009;27:1257-61. 17.8
7. Naumann U, **Bähr O**, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. *Gene Ther.* 2007;14:147-61. 4.8
6. Weiler M, **Bähr O**, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, Wick W. BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. *Cell Death Differ.* 2006;13:1156-69. 7.5
5. Tabatabai G, **Bähr O**, Mohle R, Eyupoglu IY, Boehmler AM, Wischhusen J, Rieger J, Blumcke I, Weller M, Wick W. Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. *Brain.* 2005;128:2200-11. 7.5
4. **Bähr O**, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. *Brain Pathol.* 2003;13:482-94. 3.8
3. **Bähr O**, Mader I, Zschocke J, Dichgans J, Schulz JB. Adult onset glutaric aciduria type I presenting with a leukoencephalopathy. *Neurology.* 2002;59:1802-4. 5.3
2. **Bähr O**, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53. *J Clin Invest.* 2001;107:643-6. 14.1



1. Roller A, **Bähr OR**, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M. *Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP.* *Biochem Biophys Res Commun.* 1999;259:600-5. 3.2

## Übersichtsartikel

2. Senf B, Franz K, Skorka I, Rödel C, Steinbach JP, **Bähr O**. *Psychoonkologische Behandlungsindikation und Therapieansätze bei hirneigenen Tumoren.* *Nervenheilkunde* 2012;31:630-633. 0.3
1. **Bähr O**, Steinbach JP. *State of the Art – Neuroonkologie Therapie von Patienten mit Glioblastom* *PharmaFokusZNS*, 8. Jhrg. 2011 -

## Buchkapitel

2. *Brain Tumor Imaging - Introduction* -  
**Bähr O**, Steinbach JP, Weller M.  
*In Brain Tumor Imaging, Editor: Hattingen E, Pilatus U.*  
*Springer, 2016, ISBN 978-3-642-45039-6*
1. *Long-term survivors of glioblastoma, Chapter 41* -  
*Tumors of the Central Nervous System, Volume 1, Gliomas: Glioblastoma (Part 1), Hayat, M. A. (Ed.), 1st Edition., Springer, 2011, 690 p., ISBN 978-94-007-0343-8*